Background: Younger age, male sex and presence of spinal cord lesion(s) increase the risk of conversion from radiologically isolated syndrome (RIS) to relapsing-remitting multiple sclerosis (RRMS). Elevated cerebrospinal fluid (CSF) chitinase-3-like protein 1 (CHI3L1) levels predict conversion from clinically isolated syndrome (CIS) to RRMS.
Objective: To evaluate the prognostic value of CSF CHI3L1 in RIS patients for conversion to RRMS.
Methods: We compared CSF CHI3L1 concentrations in RIS, CIS, RRMS and symptomatic controls (SCs). We analysed the influence of epidemiological, radiological and CSF parameters on the risk of clinical event.
Results: A total of 211 patients (71 RIS, 48 CIS, 50 RRMS and 42 SC) were included. CSF CHI3L1 levels were lower in RIS than in RRMS and higher in RIS with positive CSF versus negative CSF and SC. The presence of at least one spinal cord lesion was the only independent predictor of faster conversion to RRMS. Association of high CSF CHI3L1 levels, positive CSF (presence of oligoclonal bands and/or an elevated IgG index) or four Barkhof criteria with any spinal cord lesion showed a tendency for reduced mean conversion time.
Conclusion: CSF CHI3L1 correlates with positive CSF but is not an independent predictor of the risk of conversion from RIS to RRMS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1352458518767043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Longitudinal associations between cerebrospinal fluid glial activation markers, depression, and dopamine transporter availability in patients with Parkinson's disease.
J Neurol
December 2024
Department of Neurology, The Third Affiliated Hospital of Wenzhou Medical University, No.108 Wansong Road, Wenzhou, 325000, Zhejiang, China.
Background: Depression and decreased dopamine transporter (DAT) availability are prevalent in Parkinson's disease (PD), yet early predictive biomarkers are lacking. This study investigates the longitudinal associations between cerebrospinal fluid (CSF) neuroglial activation markers, sTREM2 and YKL-40, and depression, as well as DAT availability, in PD patients.
Methods: We analyzed data from 172 PD subjects and 80 matched healthy controls from a large longitudinal study.
The Role of Chitinase 3-Like-1 (YKL-40) and Proinflammatory Biomarkers in the Pathogenesis of Pediatric Tick-Borne Encephalitis in a Polish Cohort.
J Inflamm Res
December 2024
Department of Pediatric Infectious Diseases, Medical University of Bialystok, Bialystok, Poland.
Background: Chitinase 3-like-1 (CHI3L1), also known as YKL-40, is a potential biomarker for neuroinflammatory conditions. It is upregulated in Alzheimer's disease, multiple sclerosis, and traumatic brain injury. However, its involvement in pediatric tick-borne encephalitis (TBE) has not been addressed yet.
View Article and Find Full Text PDFUnveiling Potential Biomarkers in Cerebrospinal Fluid for Amyloid Pathological Positivity in Non-Demented Individuals.
J Prev Alzheimers Dis
November 2024
Prof. Xi Zhang, Department of Neurology, The Second Medical Centre, National Clinical Research Centre for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100853, China, School of Medicine, Nankai University, Tianjin, 300071, China, E-mail:
Article Synopsis
- Alzheimer's disease (AD) involves the buildup of amyloid-beta (Aβ) plaques and neurofibrillary tangles, and newly approved treatments stress the importance of early detection of Aβ abnormalities in non-demented individuals for timely intervention.
- The study analyzed cerebrospinal fluid (CSF) proteins from 474 non-demented participants to find biomarkers linked to Aβ positivity, identifying three key proteins: APOE, CHI3L1, and SMOC1 using LASSO regression.
- Among the identified proteins, SMOC1 was found to be a strong predictor of Aβ positivity and its progression, suggesting it could serve as a valuable biomarker in AD diagnosis
Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology.
Alzheimers Dement
December 2024
Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA.
Introduction: Semorinemab, an anti-tau monoclonal antibody, was assessed in two Phase II trials for Alzheimer's disease (AD). Plasma and cerebrospinal fluid (CSF) biomarkers provided insights into the drug's potential mechanism of action.
Methods: Qualified assays were used to measure biomarkers of tau, amyloidosis, glial activity, neuroinflammation, synaptic function, and neurodegeneration from participant samples in Tauriel (NCT03289143) and Lauriet (NCT03828747) Phase II trials.
Deciphering Proteomic Expression in Inflammatory Disorders: A Mass Spectrometry Exploration Comparing Infectious, Noninfectious, and Traumatic Brain Injuries in Human Cerebrospinal Fluid.
Neurotrauma Rep
September 2024
Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Article Synopsis
- The study investigates the inflammatory response of the central nervous system (CNS) to traumatic brain injury (TBI) using mass-spectrometry, comparing it to other CNS injuries and healthy controls.
- A total of 56 patients' cerebrospinal fluid (CSF) was analyzed, revealing significant differences in protein concentrations, with 55 proteins differing between TBI and noninfectious CNS disorders and 51 proteins differing between TBI and healthy controls.
- Notably, two proteins were uniquely identified in all TBI samples, and the study emphasizes the complexity of the inflammatory responses in various CNS conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!